Drug Research

India’s first mRNA-based COVID-19 vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for Phase 2/3 clinical trials, the Department of Biotechnology (DBT) said. The Pune-based biotechnology company had submitted the interim clinical data of the vaccine’s Phase...

Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate, announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company...

The US FDA has approved Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) as an adjuvant therapy for urothelial carcinoma (UC) patients at increased risk of recurrence following radical resection. A programmed death-1 (PD-1) immune checkpoint inhibitor, Opdivo can specifically harness the...

Sartorius Stedim Biotech, an international partner of the biopharmaceutical industry, has entered into a partnership with McMaster University to improve manufacturing processes of antibody and virus-based treatments for diseases such as COVID-19, cancers and genetic disorders. Using a state-of-the-art multi-column...

Zydus Pharmaceuticals Inc, USA (a 100% subsidiary of Cadila Healthcare Limited (Zydus Cadila), a leading innovation-driven, global healthcare provider, has signed a license and supply agreement with CHEMI SpA (“CHEMI”) of Italy, a subsidiary of Italfarmaco Group, to launch...

CM Life Sciences II and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration...

Gritstone bio, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, announced that the company entered into a funding agreement of up to $20.6 million with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance...